SCHEMBL19100321

SCHEMBL19100321

C1=C(COc2ccccc2)N=N[N]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 2/20 0.46
▸ NPC1 O15118 6/20 0.42
▸ RAB9A P51151 6/20 0.42
▸ SMN1; SMN2 Q16637 6/20 0.42
▸ APP P05067 1/20 0.40
▸ KCNA3 P22001 1/20 0.40
▸ CYSLTR2 Q9NS75 1/20 0.40
▸ CYSLTR1 Q9Y271 1/20 0.40
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ NISCH Q9Y2I1 1/20 0.39
▸ L3MBTL1 Q9Y468 3/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzylphenylether SCHEMBL61660 0.65 LMNA (0.74) RAB9ASMN1; SMN2APPMAOAMAOB
SCHEMBL931875 0.65 PTPRC (0.59) KCNH2NPC1RAB9ASMN1; SMN2APP
SCHEMBL850999 0.65 APP (0.78) RAB9ASMN1; SMN2APPMAOAMAOB
SCHEMBL1221701 0.64 RAB9A (0.59) KCNH2NPC1RAB9ASMN1; SMN2APP
Benzylphenylether SCHEMBL23235842 0.63 LMNA (0.71) RAB9ASMN1; SMN2APPMAOAMAOB
Benzylphenylether SCHEMBL9283359 0.63 LMNA (0.71) RAB9ASMN1; SMN2APPMAOAMAOB
Benzylphenylether SCHEMBL9549322 0.63 LMNA (0.71) RAB9ASMN1; SMN2APPMAOAMAOB
Benzylphenylether SCHEMBL27439928 0.63 LMNA (0.71) RAB9ASMN1; SMN2APPMAOAMAOB
SCHEMBL15761339 0.63 APP (0.61) KCNH2RAB9ASMN1; SMN2APPKCNA3
Benzylphenylether SCHEMBL8019776 0.63 LMNA (0.71) RAB9ASMN1; SMN2APPMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220194907-A1 PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2022-06-23 — — US disclosed
US-11259524-B2 Microbiocidal oxadiazole derivatives SYNGENTA PARTICIPATIONS AG (CH) 2022-03-01 — — US disclosed
US-20210037826-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2021-02-11 — — US disclosed
US-10798941-B2 Microbiocidal oxadiazole derivatives SYNGENTA PARTICIPATIONS AG (CH) 2020-10-13 — — US disclosed
US-20190297892-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2019-10-03 — — US disclosed
EP-3400223-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES Syngenta Participations AG (CH) 2018-11-14 — — EP disclosed
WO-2017118689-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2017-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210037826-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES PRF1, NOX1, ARG1 KCNH2 3646/4885NPC1 1320/4885RAB9A 2638/4885
US-10798941-B2 Microbiocidal oxadiazole derivatives PRF1, NOX1, ARG1 KCNH2 3717/4885NPC1 1301/4885RAB9A 2797/4885
US-20190297892-A1 MICROBIOCIDAL OXADIAZOLE DERIVATIVES PRF1, NOX1, ARG1 KCNH2 3717/4885NPC1 1301/4885RAB9A 2797/4885
US-11259524-B2 Microbiocidal oxadiazole derivatives PRF1, NOX1, ARG1 KCNH2 3646/4885NPC1 1320/4885RAB9A 2638/4885
US-20220194907-A1 PROCESS FOR THE PREPARATION OF MICROBIOCIDAL OXADIAZOLE DERIVATIVES CYP51A1, MPO, NOX5 KCNH2 2396/4885NPC1 2556/4885RAB9A 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback